Radiation Pneumonitis Clinical Trial
Official title:
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients
This randomized clinical study aims to assess whether prophylactic treatment with inhaled steroids in patients with locally advanced or concomitantly treated non-small cell lung carcinoma who are candidates for combination treatment with QT/RT or IMT + QT/RT. The main questions it aims to answer are: Whether prophylactic treatment decreases the severity of NPR on CTCAE v4.0 and RTOG scales. Whether inhaled steroid use modifies the response to radiation therapy treatment compared to patients who do not receive prophylactic inhaled steroids.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with non-small cell lung cancer (NSCLC) with unresectable locally advanced or metastatic disease (IIIA, IIIB or IV) of the classification tumor node, metastasis (TNM) of malignant lung tumors, 7th edition. - NSCLC patients candidates for concomitant treatment (chemotherapy plus radiotherapy or target therapy plus radiotherapy). - Evidence of measurable disease - Eastern Cooperative Oncology Group (ECOG) performance status = 2, Karnofsky 70-100. - Life expectancy of > 4 months at the time of screening - Patients with the ability to comply with the study and follow-up procedures. - Patients with previous surgery less than four weeks. - Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures. Exclusion Criteria: - Unstable systemic disease: active infection, heart, liver, kidney or metabolic disease; including uncontrolled chronic lung disease. - Patients treated with systemic or inhaled corticosteroids. - Patients of reproductive age without a family planning method, pregnant or lactating. - Previous diagnosis of Pneumonitis with toxicity grade = 2 by CTCAE v4.0 or RTOG scale. - Patients with disease progression. - Inspiratory flow < 90 liters / min. - Discontinue of Treatment |
Country | Name | City | State |
---|---|---|---|
Mexico | Instituto Nacional de Cancerologia | Mexico City | |
Mexico | Instituto Nacional de Enfermedades Respiratorias | Mexico City |
Lead Sponsor | Collaborator |
---|---|
Instituto Nacional de Cancerologia de Mexico | Instituto Nacional de Enfermedades Respiratorias |
Mexico,
Arrieta O, Guzman-de Alba E, Alba-Lopez LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, Allende-Perez SR, Alvarado-Aguilar S, Araujo-Navarrete ME, Argote-Greene LM, Aquino-Mendoza CA, Astorga-Ramos AM, Austudillo-de la Vega H, Aviles-Salas — View Citation
Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis. Clin Chest Med. 2017 Jun;38(2):201-208. doi: 10.1016/j.ccm.2016.12.004. Epub 2017 Mar 1. — View Citation
Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015 Sep;80(3):372-80. doi: 10.1111/bcp.12637. Epub 2015 May 28. — View Citation
Ding NH, Li JJ, Sun LQ. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr Drug Targets. 2013 Oct;14(11):1347-56. doi: 10.2174/13894501113149990198. — View Citation
Henkenberens C, Janssen S, Lavae-Mokhtari M, Leni K, Meyer A, Christiansen H, Bremer M, Dickgreber N. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-cent — View Citation
Kim S, Oh IJ, Park SY, Song JH, Seon HJ, Kim YH, Yoon SH, Yu JY, Lee BR, Kim KS, Kim YC. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis. 2014 Sep;6(9):1209-17. doi: 10.3978/j.issn.2072-1439 — View Citation
Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009 Dec;124(6 Suppl):S88-93. doi: 10.1016/j.jaci.2009.09.050. — View Citation
Simone CB 2nd. Thoracic Radiation Normal Tissue Injury. Semin Radiat Oncol. 2017 Oct;27(4):370-377. doi: 10.1016/j.semradonc.2017.04.009. — View Citation
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inop — View Citation
Vallard A, Rancoule C, Le Floch H, Guy JB, Espenel S, Le Pechoux C, Deutsch E, Magne N, Chargari C. [Medical prevention and treatment of radiation-induced pulmonary complications]. Cancer Radiother. 2017 Aug;21(5):411-423. doi: 10.1016/j.canrad.2017.03.00 — View Citation
Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets. 2010 Nov;11(11):1386-94. doi: 10.2174/1389450111009011386. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pneumonitis graded by the Common terminology criteria for adverse event v4.0. (CTCAE v4.0). | Current score for radiation pneumonitis according to symptoms and radiographic changes. Grade 0: No changes, Grade 1: Asymptomatic or mild respiratory symptoms, Grade 2: Moderate respiratory symptoms of pneumonitis (a severe cough) and radiographic changes (radiographic patches), Grade 3: Severe respiratory symptoms of pneumonitis, dense radiographic changes. Grade 4: Symptoms of acute respiratory failure requiring assisted ventilation or continuous oxygen. Grade 5: Death directly related to late effects of radiotherapy. | from the beginning of radiotherapy up to 1 year after the 1st session. | |
Primary | Pneumonitis graded by the Radiation Therapy Oncology Group score (RTOG) | Current score for radiation pneumonitis according to symptoms and radiographic changes. Grade 0: No changes, Grade 1: Asymptomatic, only radiological or tomographic findings, Grade 2: Symptomatic, does not interfere with daily activities, Grade 3: Symptomatic, interferes with daily activities, requires supplemental oxygen. Grade 4: Threatens life, needing ventilator support. Grade 5: Severe pneumonitis with fatal outcome. | from the beginning of radiotherapy up to 1 year after the 1st session. | |
Secondary | Lung cancer-associated symptoms assessment | Symptoms are evaluated with the supplementary lung cancer-specific questionnaire of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (validated Mexican-Spanish version).
It comprises 13 questions related to the assessment of dyspnoea, pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a higher level of symptoms. |
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Treatment-related side effects in lung cancer | Symptoms are evaluated with the supplementary lung cancer-specific questionnaire of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (validated Mexican-Spanish version).
It comprises 13 questions related to the assessment of dyspnoea, pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a higher level of side-effects. |
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Cognitive functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire | The cognitive functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to the assessment of short and long-term memory. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a healthy level of functioning. |
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Emotional Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire | The Emotional Functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises four questions related to the assessment of depression, anxiety, irritability, and stress. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning. |
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment | |
Secondary | Physical functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire | The Physical functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises five questions related to self-sufficiency activities (eating, walking, laying in bed or completing simple chores). The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning. |
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Role Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire | The Role functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to daily activities (work and hobbies limitation). The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning. |
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Social Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire | The Social Functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to family life and social activities. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning. |
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Respiratory symptoms evaluation using St. George respiratory questionnaire | Respiratory symptoms are evaluated using the St. George respiratory questionnaire validated to Mexican-Spanish version. It is a disease-specific instrument designed to measure the impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. | before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Dyspnea assessment by the Borg Scale Dyspnea Index (BSDI) | A system used to document the severity of the patient's shortness of breath using numbers anchored with verbal descriptions. This scale asks the patient to rate the dyspnea. It starts at number 0 where the breathing is causing no difficulty at all and progresses through to number 10 where the breathing difficulty is maximal. | before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Pulmonary function evaluation using spirometry test | Spirometry measures the inhaled and exhaled air volume as a function of time using a forced expiratory maneuver. | before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment | |
Secondary | Pulmonary function evaluation using diffusion lung capacity of carbon monoxide measurement (DLCO). | Diffusion lung capacity of carbon monoxide (DLCO) test measures the conductance of gas transfer from inspired gas to the red blood cells. | before the start of Radiotherapy and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Airway inflammatory response evaluation using the fraction of exhaled nitric oxide measurement (FeNO) | Nitric oxide concentration detected in the exhaled gas by chemiluminescence reported as particles per million. | before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. | |
Secondary | Pulmonary function evaluation using Impulse oscillometry test (IOS) | Impulse oscillometry provides a rapid, noninvasive measure of airway impedance during normal tidal breathing. | before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02490319 -
Study on the Biological Prediction Models of Radiation Pneumonitis
|
||
Completed |
NCT03796364 -
Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis
|
Phase 2 | |
Not yet recruiting |
NCT04632342 -
Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients
|
Phase 2 | |
Recruiting |
NCT05365802 -
FAPI PET for Lung Fibrosis
|
Early Phase 1 | |
Completed |
NCT01754909 -
Mitigation of Radiation Pneumonitis and Fibrosis
|
Phase 2 | |
Recruiting |
NCT05189496 -
Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis
|
N/A | |
Completed |
NCT01745484 -
Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation
|
N/A | |
Enrolling by invitation |
NCT02809456 -
Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients
|
Phase 2 | |
Recruiting |
NCT00155909 -
Risk Factors of Radiation Pneumonitis
|
N/A | |
Recruiting |
NCT06069115 -
Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
|
||
Not yet recruiting |
NCT02296281 -
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
|
Phase 2 | |
Completed |
NCT04863027 -
Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
|
||
Completed |
NCT03462524 -
Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology
|
N/A | |
Recruiting |
NCT05448703 -
A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
|
||
Recruiting |
NCT06079931 -
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
|
Phase 2 | |
Recruiting |
NCT04676828 -
Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
|
N/A | |
Recruiting |
NCT02735746 -
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis
|